Present and future of ulta-low- and low-dose triple combination therapy in hypertension: a clinical practice...

It is increasingly recognized that initial monotherapy is insufficiently effective for sustained blood pressure (BP) control in the large majority of people with hypertension. Ultra-low- and low-dose combination therapy has emerged as a strategy to overcome limitations of conventional monotherapy-based stepped care, including delayed or inadequate BP reduction, adverse-effect-related treatment discontinuation, poor adherence, and therapeutic inertia.

This review summarizes the pharmacologic rationale and clinical evidence for ultra-low- and low-dose multidrug combination therapy. To identify clinical evidence, we searched PubMed/MEDLINE, Embase, Scopus, and the Cochrane Central Register of Controlled Trials from inception to 31 March 2026, supplemented by manual reference screening. This review addresses practical questions in routine practice, including its relationship with compelling indications, cardiovascular protection, appropriate patient selection, and whether it reduces adverse effects. Future implementation as simplified, protocolized treatment and add-on approaches in high-risk populations is also discussed.

Ultra-low- and low-dose triple single-pill combination therapy should be viewed not simply as the earlier use of more antihypertensive drugs, but as a scalable treatment-delivery platform. It may support safe and earlier sustained BP control by simplifying drug selection, enabling stepwise dose escalation, reducing pill burden, improving adherence and persistence, and overcoming therapeutic inertia.